Protective effect of melatonin against Adriamycin-induced cardiotoxicity

Experimental and Therapeutic Medicine

Volumn 5, Issue 5, 2013, Pages 1496-1500

  Zhang, Yan ^a   Li, Lixin ^a   Xiang, Cheng ^a   Ma, Zhiqian ^a   Ma, Tian ^a   Zhu, Shuchai ^b  

^a FIRST HOSPITAL OF SHIJIAZHUANG   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Adriamycin; Breast cancer; Cardiotoxicity; Melatonin

Indexed keywords

DOXORUBICIN; GLUTATHIONE PEROXIDASE; LIPID PEROXIDE; MELATONIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CARDIOTOXICITY; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; HEART; HEART MUSCLE; HEART MUSCLE INJURY; IN VIVO STUDY; INTERVENTION STUDY; MICROSCOPY; NONHUMAN; RAT;

EID: 84876586475     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.989     Document Type: Article

References (35)

1. Rock E and DeMichele A: Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 133: 3785S-3793S, 2003.
2. Billingham ME, Mason JW, Bristow MR and Daniels JR: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865-872, 1978.
3. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME and Harrison DC: Early anthracycline cardiotoxicity. Am J Med 65: 823-832, 1978.
4. Chicco AJ, Schneider CM and Hayward R: Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol 289: R424-R431, 2005.
5. Chicco AJ, Schneider CM and Hayward R: Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol 47: 182-189, 2006.
6. Hydock DS, Lien CY, Schneider CM and Hayward R: Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Med Sci Sports Exerc 40: 808-817, 2008.
7. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S and Noonan DM: Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102: 14-25, 2010.
8. Lissoni P: Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol (Paris) 55: 198-200, 2007.
9. Jawed S, Kim B, Ottenhof T, Brown GM, Werstiuk ES and Niles LP: Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol 560: 17-22, 2007.
10. Lemus-Wilson A, Kelly PA and Blask DE: Melatonin blocks the stimulation effects of prolactin and human breast cancer cell growth in culture. Br J Cancer 72: 1435-1440, 1995.
11. Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A and Alonso-González C: Melatonin-estrogen interactions in breast cancer. J Pineal Res 38: 217-222, 2005.
12. Zhang Y, Zhu S and Liu J: The reverse effect and mechanism of melatonin on breast carcinoma cell line MCF-7/ADM resistant to Adriamycin. Chinese Journal of Clinical Oncology 36: 291-295, 2009 (In Chinese).
13. + breast carcinoma cell line MCF-7 to Adriamycin and its mechanism. Chinese Journal of Clinical Oncology 36: 1243-1247, 2009 (In Chinese).
14. Reiter RJ, Tan DX, Manchester LC, Paredes SD, Mayo JC and Sainz RM: Melatonin and reproduction revisited. Biol Reprod 81: 445-456, 2009.
15. Sener G, Jahovic N, Tosun O, Atasoy BM and Yeǧen BC: Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. Life Sci 74: 563-572, 2003.
16. Reiter RJ, Guerrero JM, Escames G, Pappolla MA and Acuña-Castroviejo D: Prophylactic actions of melatonin in oxidative neurotoxicity. Ann N Y Acad Sci 825: 70-78, 1997.
17. Okatani Y, Wakatsuki A and Kaneda C: Melatonin increases activities of glutathione peroxidase and superoxide dismutase in fetal rat brain. J Pineal Res 28: 89-96, 2000.
18. Reiter RJ, Acuña-Castroviejo D, Tan DX and Burkhardt S: Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci 939: 200-215, 2001.
19. Hardeland R, Pandi-Perumal SR and Cardinali DP: Melatonin. Int J Biochem Cell Biol 38: 313-316, 2006.
20. Ganguly K, Kundu P, Banerjee A, Reiter RJ and Swarnakar S: Hydrogen peroxide-mediated downregulation of matrix metalloprotease-2 in indomethacin-induced acute gastric ulceration is blocked by melatonin and other antioxidants. Free Radic Biol Med 41: 911-925, 2006.
21. Bruck R, Aeed H, Avni Y, et al: Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. J Hepatol 40: 86-93, 2004.
22. Yurtcu E, Guney Y, Ergun MA, et al: Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes. Cell Biol Int 31: 1144-1149, 2007.
23. Russo J, Tay LK and Russo IH: Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2: 5-73, 1982.
24. Dagar S, Sekosan M, Rubinstein I and Onyüksel H: Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Breast Cancer Res Treat 65: 49-54, 2001.
25. Sener-Muratoǧlu G, Paskaloǧlu K, Arbak S, Hürdaǧ C and Ayanoǧlu-Dülger G: Protective effect of famotidine, omeprazole, and melatonin against acetylsalicylic acid-induced gastric damage in rats. Dig Dis Sci 46: 318-330, 2001.
26. Maestroni GJ: The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 10: 467-476, 2001.
27. Wang WZ, Fang XH, Stephenson LL, et al: Microcirculatory effects of melatonin in rat skeletal muscle after prolonged ischemia. J Pineal Res 39: 57-65, 2005.
28. Topal T, Oter S, Korkmaz A, et al: Exogenously administered and endogenously produced melatonin reduce hyperbaric oxygen-induced oxidative stress in rat lung. Life Sci 75: 461-467, 2004.
29. Fisher PW, Salloum F, Das A, et al: Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111: 1601-1610, 2005.
30. Floyd JD, Nguyen DT, Lobins RL, et al: Cardiotoxicity of cancer therapy. J Clin Oncol 23: 7685-7696, 2005.
31. Mirunalini S, Karthishwaran K, Dhamodharan G and Shalini M: Melatonin attenuates lipid peroxidation and enhances circulatory antioxidants during mammary carcinogenesis in rats. J Biochem Tech 2: 171-174, 2010.
32. Reiter RJ and Tan DX: Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 58: 10-19, 2003.
33. Lissoni P, Barni S, Mandalá M, Ardizzoia A, Paolorossi F, et al: Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35: 1688-1692, 1999.
34. Sánchez-Suárez P, Ostrosky-Wegman P, Gallegos-Hernández F, et al: DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. Mutat Res 640: 8-15, 2008.
35. Lissoni P: Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 55: 201-204, 2007.